A new review finds that combining SGLT2 inhibitors with GLP-1 receptor agonists in heart failure is mechanistically plausible ...

The 2025 Congestive Heart Failure market size was approximately USD 9,000 million and is projected to reach approximately USD ...

You can follow a treatment plan and take medications as a doctor prescribes to manage congestive heart failure. Eat a ...

REF Phase 2 clinical trial, tovinontrine demonstrated substantial reduction in NT-proBNP, a biomarker for heart failure, in patients ...

In recent years,SGLT2 inhibitors, including dapagliflozin and empagliflozin.These have established a firm position as ...

A widely used heart failure medication called sacubitril/valsartan was associated with a lower risk of heart damage compared to placebo among high-risk cancer patients being treated with anthracycline ...

An estimated 32 million people globally have heart failure with reduced ejection fraction, a condition where the lower left chamber of the heart does a poor job of pumping blood to the rest of the ...

Patients who have been treated for heart failure and experience an improvement in their pump function are still at higher risk of heart-related death or hospitalization if they stop taking heart ...

Panelists discuss their excitement about the evolution of heart failure as a distinct specialty with multiple effective therapeutic options, the convergence of previously siloed medical disciplines ...

There were 928 patients with CHF (i.e., International Classification of Diseases, 9th Revision, Clinical Modification codes 428, 402.01, 402.11,402.91, and 404) admitted to our institution between ...

Comorbidities related to cardio-kidney-metabolic syndrome have become increasingly prevalent in patients with heart failure, ...

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines ...